FDA WARNING_LETTER - Medtech Products, Inc.

The FDA issued a Warning Letter to Medtech Products, Inc. regarding their drug product, "Murine Ear Drops for Earache Relief," following a review of its labeling and marketing information. The FDA determined the product is misbranded under sections 502 and 503 and violates section 301(a) of the Federal Food, Drug, and Cosmetic Act. Despite being marketed as an over-the-counter (OTC) drug, the product is classified as a prescription drug under section 503(b)(1) because it is intended to treat ear pain, a condition requiring diagnosis and treatment by a physician, and is not a recognized OTC indication. Consequently, the product is misbranded under section 503(b)(4) for failing to bear the "Rx only" symbol. It is further misbranded under section 502(f)(1) as its labeling lacks adequate directions for use, given that ear pain is not appropriate for OTC treatment. Additionally, the labeling is deemed false or misleading under section 502(a) by representing the product as suitable for OTC use for a condition not appropriate for self-treatment and failing to differentiate serious underlying conditions. Although labeled as homeopathic, the product does not meet the conditions of FDA's Compliance Policy Guide 7132.15 for OTC marketing, as ear pain is not a self-limiting condition. Medtech Products, Inc. must promptly correct these violations and respond within fifteen working days, detailing corrective actions and prevention measures, or face potential legal action including seizure and injunction.